Quratis trying to enter KOSDAQ

Quratis, which is developing a vaccine for tuberculosis, is drawing attention for its bid to join the KOSDAQ.

According to an investment bank (IB) industry on the 26th, Quratis is preparing to be listed as a special technology case with the aim of entering KOSDAQ as early as next year. NH Investment & Securities Co. and Shinhan Financial Investment Co. will take charge of the flagship weekly duties.

Quratis was established in 2016 on the occasion of a joint study of tuberculosis by Yonsei Medical Center and U.S. non-profit organization Idri. IDRI is a research institute that develops new drugs for incurable diseases. He also received investments from leading foundations such as the Gates Foundation.

Meanwhile, Starset Investment, SJ Investment Partners (7.17 percent), and KDB Industrial Bank of Korea (6.36 percent) have invested in Quratis, noting that they are trying to solve social problems such as tuberculosis and foot-and-mouth disease vaccines.